Preliminary dosimetric study on feasibility of multi-beam boron neutron capture therapy in patients with diffuse intrinsic pontine glioma without craniotomy

Jia-Cheng Lee¹,², Keh-Shih Chuang², Yi-Wei Chen¹,³, Fang-Yuh Hsu⁴, Fong-In Chou⁴, Sang-Hue Yen¹, Yuan-Hung Wu¹,³,⁵,⁶*

¹ Department Oncology, Taipei Veterans General Hospital, Taipei, Taiwan, ² Department of Biomedical Engineering and Environmental Sciences, National Tsing Hua University, Hsinchu, Taiwan, ³ School of Medicine, National Yang-Ming University, Taipei, Taiwan, ⁴ Nuclear Science and Technology Development Center, National Tsing Hua University, Hsinchu, Taiwan, ⁵ Institute of Public Health, National Yang-Ming University, Taipei, Taiwan, ⁶ Department of Biomedical Imaging and Radiological Sciences, National Yang-Ming University, Taipei, Taiwan

* yuanhung@gmail.com

Abstract

Diffuse intrinsic pontine glioma is a very frustrating disease. Since the tumor infiltrates the brain stem, surgical removal is often impossible. For conventional radiotherapy, the dose constraint of the brain stem impedes dose escalation. Boron neutron capture therapy (BNCT), a targeted radiotherapy, carries the potential to selectively irradiate tumors with an adequate dose while sparing adjacent normal tissue. In this study, 12 consecutive patients treated with conventional radiotherapy in our institute were reviewed to evaluate the feasibility of BNCT. NCTPlan Ver. 1.1.44 was used for dose calculations. Compared with two and three fields, the average maximal dose to the normal brain may be lowered to 7.35 ± 0.72 Gy-Eq by four-field irradiation. The mean ratio of minimal dose to clinical target volume and maximal dose to normal tissue was 2.41 ± 0.26 by four-field irradiation. A therapeutic benefit may be expected with multi-field boron neutron capture therapy to treat diffuse intrinsic pontine glioma without craniotomy, while the maximal dose to the normal brain would be minimized by using the four-field setting.

Introduction

Diffuse intrinsic pontine glioma (DIPG) is a very frustrating disease for patients, families, and doctors. Because of the tumor’s location in the brain stem, surgical removal is often impossible. For radiotherapy, the dose constraint of the brain stem impedes dose escalation. Almost all patients expire within 1 year of diagnosis despite radical treatment. Boron neutron capture therapy (BNCT), a targeted radiotherapy, may have the potential to deliver an adequate radiation dose to the tumor cells while sparing the normal brain stem.
BNCT applies thermal neutrons to tumors that take up $^{10}$B selectively. Currently, there are two $^{10}$B-containing drugs being used in human clinical trials for BNCT: BSH (disodium mercaptoundecahydrododecaborate) and BPA ($p$-Boron-L-phenylalanine). Tumors tend to take up these drugs preferentially, such that a higher $^{10}$B concentration can be achieved in tumors than in normal tissue. The tumor/normal ratio (T/N ratio) is the ratio of the concentration of the $^{10}$B-containing drug taken up by the tumor relative to that of normal tissue. The neutron-capture reaction ($^{10}$B(n,$\alpha$)$^7$Li) produces two high linear energy transfer (LET) particles with approximately a 10-μm range that damage tumor cells while substantially sparing surrounding normal tissues (Fig 1). With a high T/N ratio, targeted radiotherapy is thus made possible.

BNCT use has been limited by the advantage depth (AD), at which the dose to the tumor is the same as the maximal dose to the normal tissue on the path of the neutron beam (Fig 2). Using a 3.5 of ratio of BPA boron concentrations in tumor and normal tissue, it was found that AD was 8.5 cm. Tumor tissue deeper than the AD would be without therapeutic benefit. Attempts to treat DIPG with BNCT have been made in Japan [1], but all 6 patients treated in that study expired. The failure in that study may be partially attributed to the invasiveness of the treatment at that time and to the uncertainty of the true T/N ratio, making accurate dose estimation difficult. Since the neutron source used in that study was a thermal neutron, which has lower energy than the current standard epithermal neutron, the AD was thus inadequate without craniotomy. The patients in that study were treated intra-operatively during craniotomy. Moreover, positron emission tomography (PET) was not performed to estimate the boron uptake for dosimetric estimation, which might have led to less accurate estimations than does the current standard of performing PET as a part of dose calculation.

![Fig 1. BNCT, as a targeted radiotherapy, may selectively damage cancer cells while sparing normal ones.](https://doi.org/10.1371/journal.pone.0180461.g001)
Efforts to increase the energy of the neutron source have been made. Neutron sources with higher energy, such as epithermal neutrons, have been used to perform BNCT as far back as 1994 [2]. With better penetration, thus a deeper AD, it might be possible to treat DIPG with BNCT without craniotomy. However, to the best of our knowledge, there has been no published study treating DIPG with BNCT in the era of epithermal neutron sources.

In this study, we aimed to perform a preliminary dosimetric investigation on the feasibility of BNCT without craniotomy in patients with DIPG and to compare the benefits of dose distribution by increasing the field number from two to four.

**Materials and methods**

**Neutron source**

An epithermal neutron test beam of the Tsing-Hua open-pool reactor (THOR) was constructed in 1998 for studying BNCT. A rebuilt epithermal beam port for BNCT at THOR was finished in the summer of 2004. The first clinical trial of BNCT in THOR for recurrent head and neck cancer was conducted between 2009 and 2013 [3, 4]. The AD of THOR is 8.5 cm [5].

**Patient selection**

In this study, simulation computerized tomography (CT) scans of 12 consecutive patients with DIPG treated with external beam photon radiotherapy in Taipei Veterans General Hospital (TVGH), Taipei, Taiwan, from 2008 to 2015 were used for dose calculation. The patients ranged in age from 4 years to 53 years, with median age of 10 years. This study has been approved.

![Fig 2. Advantage depth.](https://doi.org/10.1371/journal.pone.0180461.g002)
by Institutional Review Board, Taipei Veterans General Hospital (No. 2016-05-018CC). The study has been conducted according to the principles expressed in the Declaration of Helsinki. The data were analyzed anonymously.

The treatment planning systems

We used NCTPlan Ver. 1.1.44 [6, 7], developed by the Harvard/MIT BNCT group, for treatment planning. Because NCTPlan requires CT images in tagged image file format (TIFF) files, we utilized ImageJ Ver. 1.48v [8–10] and in-house code to transform the CT images in Digital Imaging and Communications in Medicine (DICOM) to TIFF format with 256 × 256 pixels, 125 slices, and a 2-mm slice thickness. The gray level of the CT images was set to 8 bits. NCTPlan converted the input images into 21 × 21 × 25 voxels and 56 different materials, which was defined in the International Commission on Radiation Units and Measurements 46 (ICRU-46) report [11] for calculations. The doses were calculated by F4 tally and kinetic energy released in matter factors in Monte Carlo N-Particle Transport Code, Ver. 4C [12].

Dose-rate scaling factor (DRSF) is defined here as normalization factor derived individually for each dose component in a BNCT in-phantom radiation field that provides the best agreement between measured and computed data. The adjusted computed dose, \( D_{\text{adj}}(\text{dose component}) \), at any position within the ellipsoidal head phantom was then given by Eqs (1)–(4).

\[
D_{\text{adj}}(\text{thermal}) = \text{DRSF}(\text{thermal}) \times D(\text{thermal})
\]

\[
D_{\text{adj}}(\text{fast}) = \text{DRSF}(\text{fast}) \times D(\text{fast})
\]

\[
D_{\text{adj}}(\text{photon}) = \text{DRSF}(\text{photon}) \times D(\text{photon})
\]

\[
D_{\text{adj}}(B^{10}) = \text{DRSF}(B - 10) \times D(B - 10)
\]

The dose-rate scaling factor values derived from the measured and computed depth-dose-rate distributions by least-squares criteria were 0.64, 1.39, 0.96, and 0.65, for thermal neutron, fast neutron, photon, and B-10, respectively [13]. Although the T/N ratio between boron concentrations in DIPG remains unknown, because most DIPGs are composed of glioblastoma, we assumed a T/N ratio of 3.5 according to a previous glioblastoma study [14].

Based on the results of the Monte Carlo calculations, to compute the total biologically weighted dose (RBE dose), we used the following parameters for our estimations: a relative biological effectiveness (RBE) factor of 3.8 and 1.3 for BPA in the tumor cells and brain, respectively. A RBE of 3.2 for THOR epithermal neutron beam high-LET components, such as the products of thermal neutron capture in nitrogen and fast neutrons, and a RBE of 0.5 for photon [13]. The default neutron power and flux were 1.2 MW and 1.28 × 10^9 (n·cm^{-2}·s^{-1}), respectively, for the conditions of THOR [15]. RBE dose was determined by Eq (5):

\[
\text{RBE dose} = \text{RBE(thermal))} \times D_{\text{adj}}(\text{thermal}) + \text{RBE(fast)} \times D_{\text{adj}}(\text{fast}) + \text{RBE(photons)} \times D_{\text{adj}}(\text{photon}) + \text{RBE}(B - 10) \times D_{\text{adj}}(B - 10)
\]

We measured the distance from the body surface to the deepest tumor depths on CT images using the Eclipse version 13 treatment planning system (Varian Medical Systems, Palo Alto, CA, USA). Dosimetry of multiple fields was calculated from two to four fields with 14 cm-diameter collimator. The directions used in the two-field (2F) plan were left (90˚) and right (270˚). The directions used in the three-field (3F) plan were left anterior oblique (60˚), right anterior oblique (300˚), and posterior (180˚). The directions used in the four-field (4F) plan...
were anterior (0˚), left (90˚), posterior (180˚), and right (270˚). The weightings of the multiple fields from each direction were optimized manually until the difference of the maximal dose to normal tissues of each direction was within 10%. The dose prescription was 20 Gy-Eq in 80% of the clinical target volume (CTV), as prescribed in a clinical trial of BNCT for recurrent head and neck cancer in our institution [4]. We also calculated the estimated total beam-on time for the 2F, 3F, and 4F plans.

Delineation of target volume and normal tissue

The CTV and normal tissue were delineated by one radiation oncologist and verified by another on NCTPlan according to the MRI images that were registered with the simulation CT image on the Eclipse treatment planning system. The CTV contains the gross extent of the malignant growth and subclinical microscopic malignant disease, as defined by ICRU 62 [16].

Dosimetric evaluation

The dose distribution in the CTV in each plan was evaluated by the following parameters: CTV minimal dose (CTV$_{\text{min}}$), CTV maximal dose (CTV$_{\text{max}}$), minimal dose to 95% of the CTV volume (CTV$_{95\%}$), and homogeneity index (HI). HI was applied to evaluate the homogeneity in CTV as defined by [17]:

$$ HI = \frac{D_5}{D_{95}} $$

where $D_5$ and $D_{95}$ represent minimum dose in 5% and 95% of CTV, respectively.

The therapeutic gain, defined as the ratio of minimal dose to CTV and maximal dose to normal tissue (CTV$_{\text{min/NT_{max}}}$), was calculated. The integral dose (ID) of radiation delivered to the normal tissue was defined as $ID(Gy-Eq \cdot L) = \bar{D}(Gy-Eq) \cdot V(L)$, where $\bar{D}(Gy-Eq)$ is the mean dose delivered to volume $V(L)$ as noted by Aoyama et al. [18]. Avoidance to organs at risk, including the normal brain (NB), optic nerve (ON), and circle of Willis (CW), was evaluated by the following parameters: mean dose (D$_{\text{mean}}$), maximum dose (D$_{\text{max}}$), and ID of the NB, ON, and CW, respectively.

Statistical analysis

All statistical tests were performed using SPSS software (release 17.0, SPSS Inc., Chicago, IL, USA). One-way analysis of variance was used to compare dosimetric differences of the 2F, 3F, and 4F BNCT plans. Tests were two-sided. The differences were considered statistically significant if $P \leq 0.05$.

Results

Maximal tumor depths and dose distribution

The maximal depth of tumors from body surfaces based on CT images with 0˚, 60˚, 90˚, 180˚, 270˚, and 300˚ beam angles are shown in Table 1. This table shows that the mean maximal tumor depths in six different beam directions were larger than the AD. Use of a single beam angle can result in aggressive dose to the peritumoral area.

| Beam angle | 0˚ | 60˚ | 90˚ | 180˚ | 270˚ | 300˚ |
|------------|----|-----|-----|------|------|-----|
| Mean deepest tumor depth (cm) | 11.76 ± 0.65 | 9.77 ± 0.80 | 9.52 ± 0.74 | 9.19 ± 0.62 | 9.60 ± 0.80 | 10.04 ± 0.68 |
| Depth range (cm) | 10.79–12.78 | 8.53–10.85 | 8.3–10.31 | 8.52–10.18 | 8.56–10.76 | 9.11–11.00 |

https://doi.org/10.1371/journal.pone.0180461.t001

https://doi.org/10.1371/journal.pone.0180461.t001
direction for DIPG is without therapeutic benefit. The dose distributions and dose volume histogram of 2F, 3F, and 4F irradiation are shown in Figs 3 and 4. With 4F irradiation, the dose affecting normal tissue can be reduced.

Target dosimetric evaluation

The minimal, maximal, and mean dose to CTV and CTV$_{95\%}$ are shown in Table 2. There was no significant difference in CTV$_{\text{min}}$, CTV$_{\text{max}}$, CTV$_{\text{mean}}$, and CTV$_{95\%}$ among the three settings. CTV$_{\text{min}}$/NT$_{\text{max}}$, HI, and beam-on time are shown in Table 3. The CTV$_{\text{min}}$/NT$_{\text{max}}$ of the 4F ($P < 0.001$) and 3F ($P = 0.005$) were better than that of 2F. CTV$_{\text{min}}$/NT$_{\text{max}}$ of 4F was slightly larger than that of 3F ($P = 0.064$). HI and beam-on time were not significantly different among the three plans.

Radiation exposure of organs at risk

The volume, D$_{\text{mean}}$, D$_{\text{max}}$, and ID of the NB, ON, and CW for 2F, 3F, and 4F plans are listed in Table 4.
There was no significantly difference in $D_{\text{mean}}$ and ID of NB among the three plans. $D_{\text{max}}$ to NB was lowered with the 4F plan. $D_{\text{mean}}$ and $D_{\text{max}}$ to optic nerves were higher by 4F. Compared with the 2F plan, 4F yielded significant increases in ID to the optic nerves.

Table 2. Patient number, age, and CTV dosimetric parameter of 2F, 3F, and 4F plans.

| Patient number | Age, years | $CTV_{\text{min}}$ (Gy-Eq) | $CTV_{\text{max}}$ (Gy-Eq) | $CTV_{\text{mean}}$ (Gy-Eq) | $CTV_{95\%}$ (Gy-Eq) |
|----------------|------------|-----------------------------|-----------------------------|-----------------------------|----------------------|
|                | 2F         | 3F                          | 4F                          | 2F                          | 3F                   | 4F                   |
| 1              | 32         | 17.42                       | 18.42                       | 17.96                       | 24.84                | 21.05                | 21.08                | 18.71                | 19.20                | 18.95                |
| 2              | 13         | 16.71                       | 17.03                       | 16.91                       | 27.72                | 23.90                | 23.85                | 21.36                | 21.01                | 21.22                | 18.35                | 18.22                | 18.03                |
| 3              | 6          | 17.64                       | 17.45                       | 17.34                       | 24.42                | 23.36                | 23.74                | 20.66                | 20.74                | 21.05                | 18.99                | 18.85                | 18.80                |
| 4              | 53         | 17.30                       | 17.66                       | 17.05                       | 25.49                | 25.89                | 24.12                | 20.67                | 21.09                | 21.02                | 19.11                | 18.82                | 18.65                |
| 5              | 38         | 17.36                       | 17.36                       | 17.81                       | 26.04                | 26.04                | 23.02                | 20.94                | 21.32                | 20.92                | 19.09                | 19.02                | 18.90                |
| 6              | 8          | 18.51                       | 18.07                       | 18.32                       | 23.37                | 23.74                | 22.96                | 20.70                | 20.91                | 20.84                | 19.42                | 19.16                | 18.94                |
| 7              | 8          | 16.87                       | 17.36                       | 17.31                       | 27.07                | 25.14                | 24.72                | 21.47                | 21.20                | 21.61                | 18.82                | 18.86                | 18.82                |
| 8              | 5          | 17.85                       | 17.53                       | 17.99                       | 24.99                | 24.49                | 23.65                | 20.85                | 21.13                | 21.01                | 18.93                | 18.93                | 19.01                |
| 9              | 4          | 17.55                       | 17.32                       | 18.74                       | 24.63                | 23.98                | 25.34                | 21.04                | 21.26                | 22.69                | 18.77                | 18.65                | 20.07                |
| 10             | 12         | 16.64                       | 17.22                       | 17.45                       | 25.67                | 28.94                | 26.18                | 20.6                | 21.42                | 21.47                | 19.01                | 18.95                | 18.89                |
| 11             | 4          | 16.50                       | 16.94                       | 15.89                       | 24.31                | 23.52                | 22.63                | 21.16                | 21.19                | 19.96                | 18.24                | 18.47                | 18.30                |
| 12             | 13         | 15.62                       | 17.26                       | 17.11                       | 17.26                | 25.47                | 24.63                | 21.54                | 21.47                | 21.64                | 18.00                | 18.18                | 18.41                |
| Mean           |            | 16.30                       | 17.16                       | 17.47                       | 24.65                | 24.88                | 24.00                | 21.00                | 21.16                | 21.21                | 18.79                | 18.78                | 18.81                |
| SD             |            | 15.90                       | 0.75                        | 0.42                        | 0.75                 | 2.62                 | 1.57                 | 1.06                 | 0.33                 | 0.21                 | 0.64                 | 0.41                 | 0.33                 | 0.50                 |

P-value

2F vs. 3F ($P = 0.532$) 2F vs. 3F ($P = 0.955$) 2F vs. 3F ($P = 0.690$) 2F vs. 3F ($P = 0.998$) 2F vs. 4F ($P = 0.485$) 2F vs. 4F ($P = 0.696$) 2F vs. 4F ($P = 0.512$) 2F vs. 4F ($P = 0.987$) 3F vs. 4F ($P = 0.997$) 3F vs. 4F ($P = 0.516$) 3F vs. 4F ($P = 0.955$) 3F vs. 4F ($P = 0.975$)

https://doi.org/10.1371/journal.pone.0180461.t002

There was no significantly difference in $D_{\text{mean}}$ and ID of NB among the three plans. $D_{\text{max}}$ to NB was lowered with the 4F plan.

$D_{\text{mean}}$ and $D_{\text{max}}$ to optic nerves were higher by 4F. Compared with the 2F plan, 4F yielded significant increases in ID to the optic nerves.

Table 3. $CTV_{\text{min}}/NT_{\text{max}}$, HI, and beam-on time of 2F, 3F and 4F plans.

| Patient number | $CTV_{\text{min}}/NT_{\text{max}}$ | HI | Beam-on time (min) |
|----------------|-----------------------------------|----|-------------------|
|                | 2F (A)                            | 3F (B)                            | 4F (C) |
| 1              | 1.97                              | 2.51                              | 2.77   |
| 2              | 1.48                              | 2.05                              | 2.24   |
| 3              | 1.75                              | 2.16                              | 2.40   |
| 4              | 1.4                               | 1.64                              | 1.92   |
| 5              | 1.45                              | 1.92                              | 2.36   |
| 6              | 2.23                              | 2.42                              | 2.71   |
| 7              | 1.55                              | 2.03                              | 2.32   |
| 8              | 1.82                              | 2.24                              | 2.62   |
| 9              | 2.04                              | 2.36                              | 2.64   |
| 10             | 1.25                              | 1.81                              | 2.06   |
| 11             | 2.05                              | 2.45                              | 2.43   |
| 12             | 1.68                              | 1.92                              | 2.40   |
| Mean           | 1.72                              | 2.13                              | 2.41   |
| SD             | 0.31                              | 0.28                              | 0.26   |

P-value

2F vs. 3F ($P = 0.005$)* 2F vs. 3F ($P = 0.489$) 2F vs. 3F ($P = 0.470$) 2F vs. 4F ($P < 0.001$)* 2F vs. 4F ($P = 0.988$) 2F vs. 4F ($P = 0.296$) 3F vs. 4F ($P = 0.064$) 3F vs. 4F ($P = 0.404$) 3F vs. 4F ($P = 0.942$)

https://doi.org/10.1371/journal.pone.0180461.t003
There was no significant difference in ID to CW among the three settings. The $D_{\text{max}}$ to CW by the 4F plan was higher than that of the 2F plan. The dose constraints may be fulfilled by all three settings.

**Discussion**

In this study, we reviewed the simulation CT scans of 12 consecutive patients treated by conventional radiotherapy in our institution. We found that, without craniotomy, the prescribed

| Organ | Volume (cm$^3$) | Parameter | 2F $D_{\text{mean}}^a$ | 3F $D_{\text{mean}}^a$ | 4F $D_{\text{mean}}^a$ | P-value | Tolerance reference |
|-------|----------------|----------|----------------------|----------------------|----------------------|---------|---------------------|
| NB    | 1166.21 ± 121.20 | $D_{\text{max}}^a$ | 4.66 ± 0.40 | 4.66 ± 0.42 | 4.56 ± 0.35 | 2F vs. 3F (P = 0.801) | Max. dose < 13 Gy-Eq [19] |
|       |                | $D_{\text{max}}^a$ | 10.22 ± 1.72 | 8.34 ± 1.10 | 7.35 ± 0.72 | 2F vs. 3F (P = 0.160) | Max. dose < 13 Gy-Eq [19] |
|       |                | ID $^b$    | 523.77 ± 93.89 | 547.03 ± 101.76 | 534.68 ± 94.46 | 2F vs. 3F (P = 0.842) |

| Organ | Volume (cm$^3$) | Parameter | 2F $D_{\text{mean}}^a$ | 3F $D_{\text{mean}}^a$ | 4F $D_{\text{mean}}^a$ | P-value | Tolerance reference |
|-------|----------------|----------|----------------------|----------------------|----------------------|---------|---------------------|
| L-ON  | 1.72 ± 0.55    | $D_{\text{mean}}$ | 4.23 ± 0.70 | 5.60 ± 0.57 | 6.09 ± 0.44 | 2F vs. 3F (P = 0.139) | Max. dose < 10 Gy[20] |
|       |                | $D_{\text{max}}$ | 5.09 ± 0.51 | 6.07 ± 0.68 | 6.60 ± 0.44 | 2F vs. 3F (P = 0.087) |
|       |                | ID        | 0.69 ± 0.19 | 0.96 ± 0.32 | 1.04 ± 0.31 | 2F vs. 3F (P = 0.077) |

| Organ | Volume (cm$^3$) | Parameter | 2F $D_{\text{mean}}^a$ | 3F $D_{\text{mean}}^a$ | 4F $D_{\text{mean}}^a$ | P-value | Tolerance reference |
|-------|----------------|----------|----------------------|----------------------|----------------------|---------|---------------------|
| R-ON  | 1.59 ± 0.38    | $D_{\text{mean}}$ | 4.23 ± 0.50 | 5.59 ± 0.55 | 6.19 ± 0.55 | 2F vs. 3F (P = 0.038) | Max. dose < 10 Gy[20] |
|       |                | $D_{\text{max}}$ | 5.24 ± 0.48 | 6.11 ± 0.64 | 6.65 ± 0.51 | 2F vs. 3F (P = 0.077) |
|       |                | ID        | 0.66 ± 0.14 | 0.89 ± 0.24 | 0.98 ± 0.24 | 2F vs. 3F (P = 0.038) |

| Organ | Volume (cm$^3$) | Parameter | 2F $D_{\text{mean}}^a$ | 3F $D_{\text{mean}}^a$ | 4F $D_{\text{mean}}^a$ | P-value | Tolerance reference |
|-------|----------------|----------|----------------------|----------------------|----------------------|---------|---------------------|
| CW    | 1.00 ± 0.22    | $D_{\text{mean}}$ | 4.79 ± 0.36 | 5.26 ± 0.40 | 5.59 ± 0.31 | 2F vs. 3F (P = 0.096) | Max. dose <12 Gy-Eq[1] |
|       |                | $D_{\text{max}}$ | 5.35 ± 0.38 | 5.60 ± 0.43 | 5.99 ± 0.37 | 2F vs. 3F (P = 0.063) |
|       |                | ID        | 0.48 ± 0.10 | 0.48 ± 0.18 | 0.51 ± 0.20 | 2F vs. 3F (P = 0.999) |

NB: normal brain, L-ON: left optic nerve, R-ON: right optic nerve, CW: circle of Willis, $D_{\text{mean}}$: mean dose, $D_{\text{max}}$: maximum dose, ID: integral dose.

$^a$ in Gy-Eq.

$^b$ in cGy-Eq-L

https://doi.org/10.1371/journal.pone.0180461.t004
A therapeutic dose to the CTV may be fulfilled while complying with the dose constraints to the NB, ON, and CW. Specifically, a therapeutic benefit may be achieved by applying multi-field BNCT to treat DIPG without craniotomy, while the therapeutic gain, defined by $CTV_{\text{min}}/NT_{\text{max}}$, was greatest in 3F and 4F plans. To the best of our knowledge, the current study is the first to show that, dosimetrically, treatment of DIPG by BNCT without craniotomy may be feasible.

Besides the normal tissue constraints referred to in Table 4, Harvard-MIT and the Brookhaven National Laboratory Phase I and Phase I/II clinical trials found that the doses associated with a 50% incidence for somnolence ($ED_{50} \pm SE$) were $6.2 \pm 1.0$ Gy-Eq for the average whole-brain dose and $14.1 \pm 1.8$ Gy-Eq for the peak brain dose [21]. In the present study, we found that when multi-field BNCT was applied, the mean and maximal doses to the brain were below the aforementioned $ED_{50}$ levels.

The Harvard-MIT trial data also suggested that the increased number of radiation fields may be the major reason for increased average whole-brain dose. However, in the present study, we found that when we applied a four-field plan, the average whole-brain dose decreased. The reason for this discrepancy is likely due to the fact that in the previous trial, the clinicians increased radiation fields for dose escalation. Instead, in the present study, the prescribed dose remained the same, while the number of radiation fields was increased.

For a disease involving predominantly children, the duration of treatment is crucial. In this study, we found that the average beam-on time was within 1 hour, which should be feasible for treatment of pediatric patients.

The outcome of BNCT in treating glioblastoma has been shown to be comparable with conventional radiotherapy with concurrent temozolomide, with a much shorter treatment duration [22]. The present findings suggest that treatment of DIPGs with multi-beam BNCT may have a therapeutic benefit dosimetrically. Given that most DIPGs are glioblastomas, a similar outcome may be expected. A clinical trial is warranted for this grave disease.

The actual $T/N$ ratio of DIPG is unknown. The normal tissue tolerance of pediatric patients may be different from that of adults. To further reduce the dose to normal tissues, blockers should be applied in future studies.

Although the beam-on time in two, three, and four port irradiation was almost the same, if we consider the interval time for set-up of the patient, the treatment time in four-port irradiation may be much longer compared with two-port irradiation.

**Conclusions**

Therapeutic benefits may be achieved using multi-field BNCT in patients with DIPG. The maximal dose to normal brain would be minimal and the prescription dose to tumor would be higher by four fields. To initiate a clinical trial on this devastating disease might be worthwhile.

**Acknowledgments**

We would like to thank all BCNT staff members of the radiation oncology at VGHTPE (Taipei Veterans General Hospital) and Institute of Nuclear Engineering and Science at NTHU (National Tsing-Hua University). The authors are grateful for the financial support from grants of Taipei Veterans General Hospital (No: V105A-046, V105A-013, V106A-007, and V106A-016) and Taipei Veterans General Hospital-National Yang Ming University Excellent Physician Scientists Cultivation Program, No. 105-V-B-107. Part of this manuscript was presented at the 17th International Congress on Neutron Capture Therapy, Columbia, Missouri, USA, October, 2016.
Author Contributions

Conceptualization: J-CL K-SC Y-WC F-YH S-HY Y-HW.
Data curation: J-CL K-SC Y-WC F-YH S-HY Y-HW F-IC.
Formal analysis: J-CL Y-HW.
Funding acquisition: J-CL Y-HW.
Investigation: J-CL K-SC Y-WC Y-HW.
Methodology: J-CL K-SC Y-WC Y-HW.
Project administration: J-CL K-SC Y-WC Y-HW.
Resources: J-CL Y-WC F-YH F-IC Y-HW.
Software: F-YH.
Supervision: K-SC Y-WC F-YH F-IC S-HY Y-HW.
Validation: K-SC Y-WC F-YH F-IC S-HY Y-HW.
Visualization: J-CL K-SC Y-WC F-YH F-IC S-HY Y-HW.
Writing – original draft: J-CL Y-HW.
Writing – review & editing: K-SC Y-WC F-YH F-IC S-HY.

References

1. Nakagawa Y, Kageji T, Mizobuchi Y, Kumada H, Nakagawa Y. Clinical results of BNCT for malignant brain tumors in children. Applied Radiation and Isotopes. 2009; 67(7):S27 –S30.
2. Rogus RD, Harling OK, Yanch JC. Mixed field dosimetry of epithermal neutron beams for boron neutron capture therapy at the MITR-II research reactor. Medical physics. 1994; 21(10):1611–25. https://doi.org/10.1118/1.597267 PMID: 7869994
3. Wang L-W, Chen Y-W, Ho C-Y, Liu Y-WH, Chou F-I, Liu Y-H, et al. Fractionated Boron Neutron Capture Therapy in Locally Recurrent Head and Neck Cancer: A Prospective Phase I/II Trial. International Journal of Radiation Oncology*Biology*Physics. 2016; 95(1):396–403.
4. Wang L-W, Chen Y-W, Ho C-Y, Liu Y-WH, Chou F-I, Liu Y-H, et al. Fractionated BNCT for locally recurrent head and neck cancer: experience from a phase I/II clinical trial at Tsing Hua open-pool reactor. Applied Radiation and Isotopes. 2014; 88:23–7. https://doi.org/10.1016/j.apradiso.2013.11.134 PMID: 24369888
5. Tung C, Wang Y, Hsu F, Chang S, Liu YH. Characteristics of the new THOR epithermal neutron beam for BNCT. Applied radiation and isotopes. 2004; 61(5):861–4. https://doi.org/10.1016/j.apradiso.2004.05.066 PMID: 15308158
6. Gonzalez S, Santa Cruz GA, Yam C. NCTPlan. The new PC version of MacNCTPlan improvements and validation of the treatment planning system. 2003.
7. Kiger W III, Santa Cruz G, González S, Hsu F, Riley K, Binns P, et al. Verification and validation of the NCTPlan treatment planning program. Research and Development in Neutron Capture Therapy Monduzzi Editore, Bologna, Italy. 2002:613–6.
8. Rasband WS. ImageJ, U. S. National Institutes of Health, Bethesda, Maryland, USA, (http://imagej.nih.gov/ij). 1997–2012.
9. Schneider CA, Rasband WS, Eliceiri KW. NIH Image to ImageJ: 25 years of image analysis. Nat methods. 2012; 9(7):671–5. PMID: 22930834
10. Abrámoff MD, Magalhães PJ, Ram SJ. Image processing with ImageJ. Biophotonics international. 2004; 11(7):36–42.
11. ICRU. Photon, Electron, Proton and Neutron Interaction Data for Body Tissues. International Commission on Radiation Units and Measurements Bethesda, MD; 1992.
12. Pelowitz D. MCNPX User's Manual Version 2.7. 0—LA-CP-11-00438. Los Alamos National Laboratory. 2011.

13. Hsu F, Liu M, Tung C, Liu YH, Chang C, Liu H, et al. Assessment of dose rate scaling factors used in NCTPlan treatment planning code for the BNCT beam of THOR. Applied Radiation and Isotopes. 2009; 67(7):S130–S3.

14. Zamenhof R, Palmer M, Busse P. Clinical treatment planning for subjects undergoing boron neutron capture therapy at Harvard-MIT. neutron capture therapy. 2001:216.

15. Liu Y-H, Nievaart S, Tsai P-E, Liu H-M, Moss R, Jiang S-H. Neutron spectra measurement and comparison of the HFR and THOR BNCT beams. Applied Radiation and Isotopes. 2009; 67(7):S137–S40.

16. Morgan-Fletcher S. Prescribing, recording and reporting photon beam therapy (Supplement to ICRU Report 50), ICRU Report 62. ICRU, pp. ix+ 52, 1999 (ICRU Bethesda, MD) $65.00 ISBN 0-913394-61-0. The British Journal of Radiology. 2001; 74(879):294-.

17. Semenenko VA, Reitz B, Day E, Qi XS, Mitten M, Li XA. Evaluation of a commercial biologically based IMRT treatment planning system. Medical physics. 2008; 35(12):5851–60. https://doi.org/10.1118/1.3013556 PMID: 19175141

18. Aoyama H, Westerly DC, Mackie TR, Olivera GH, Bentzen SM, Patel RR, et al. Integral radiation dose to normal structures with conformal external beam radiation. International Journal of Radiation Oncology*Biology*Physics. 2006; 64(3):962–7.

19. Kawabata S, Miyatake S-I, Hiramatsu R, Hirota Y, Miyata S, Takekita Y, et al. Phase II clinical study of boron neutron capture therapy combined with X-ray radiotherapy/temozolomide in patients with newly diagnosed glioblastoma multiforme—Study design and current status report. Applied Radiation and Isotopes. 2011; 69(12):1796–9. https://doi.org/10.1016/j.apradiso.2011.03.014 PMID: 21459588

20. Benedict SH, Yenice KM, Fallowill D, Galvin JM, Hinson W, Kavanagh B, et al. Stereotactic body radiation therapy: the report of AAPM Task Group 101. Medical physics. 2010; 37(8):4078–101. https://doi.org/10.1118/1.3438081 PMID: 20879569

21. Marcus KJ, Dutton SC, Barnes P, Coleman CN, Pomeroy SL, Goumnerova L, et al. A phase I trial of etanidazole and hyperfractionated radiotherapy in children with diffuse brainstem glioma. International Journal of Radiation Oncology*Biology*Physics. 2003; 55(5):1182–5.

22. Sköld K, Gorlia T, Pelletier L, Giusti V, H-Stenstam B, Hopewell J. Boron neutron capture therapy for newly diagnosed glioblastoma multiforme: an assessment of clinical potential. The British journal of radiology. 2014.